Evidence map›Paper›PMID 40881885›Full record

ArticleFrontiers in oncology2025

Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseudo-syndrome of anterior uveitis.

Cong Zhao, Jiaqi Chen, Hongji Liu, Yan Dai

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Cong ZhaoEyeSchool of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Jiaqi ChenEyeSchool of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Hongji LiuDepartment of Ophthalmology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.
Yan DaiDepartment of Ophthalmology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the second most common primary site for intraocular metastatic tumors, with the most frequent metastatic site being the choroid. However, cases of intraocular metastasis of lung cancer presenting as anterior uveitis or secondary glaucoma are rare and often misdiagnosed. Here, we report a case of a lung adenocarcinoma stage IV patient, who presented with anterior uveitis as the initial symptom without respiratory symptoms. After 28 months of follow-up, the patient received targeted treatment with Alectinib hydrochloride capsules and a series of timely ophthalmic surgeries. Following these treatments, the patient's intraocular and intracranial metastatic lesions disappeared, the primary pulmonary lesion significantly shrank, and the best corrected visual acuity (BCVA) improved from HM/30cm to 1.0. No significant toxic side effects were observed during the treatment, and the prognosis was favorable. The patient is currently living and working normally without complications. This case highlights the importance of considering metastatic tumors in patients with refractory anterior uveitis. Combined multimodal imaging and fluid biopsy can improve the early diagnosis rate of intraocular metastases. Targeted therapy based on genetic mutation detection, along with the appropriate timing for ophthalmic surgery, is crucial for improving patient prognosis.

Indexed as

alectinibALK mutationcase reportmetastasisnon-small cell lung cancer

Identifiers

PMID40881885
PMCPMC12380888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.